Liviu Klein, MD
Advanced Heart Failure and Transplant Cardiology · San Francisco, CANPI 1235199340
Payments from drug & device makers
Across 510 payments — averaging $2167.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procyrion, Inc.$246K
- Paragonix Technologies, Inc.$227K
- Edwards Lifesciences$219K
- Abbott$122K
- Transmedics, Inc.$98K
- Medtronic$69K
- plus $123K from 16 others
Across 11 payments — averaging $540.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$6K
What the payments were for
- Consulting fees$120,00654%
- Speaking & faculty fees$60,47727%
- Travel & lodging$30,50114%
- Food & beverage$12,4446%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procyrion, Inc. | 4 | $245,864 |
| Paragonix Technologies, Inc. | 11 | $227,358 |
| Edwards Lifesciences | 37 | $219,270 |
| Abbott | 235 | $122,399 |
| Transmedics, Inc. | 10 | $98,141 |
| Medtronic(2 entities) | 107 | $69,324 |
| ZOLL Respicardia, Inc. | 19 | $35,157 |
| Impulse Dynamics (USA) Inc. | 5 | $29,164 |
| Cvrx, Inc. | 27 | $23,064 |
| Nuwellis, Inc. | 7 | $16,461 |
| Boston Scientific | 20 | $8,514 |
| Abiomed | 17 | $5,126 |
| ZOLL Circulation Inc | 1 | $2,500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,100 |
| W. L. Gore & Associates, Inc. | 1 | $600 |
| ZOLL Medical Corporation | 1 | $508 |
| Vifor (international) Ltd. | 1 | $500 |
| Boehringer Ingelheim | 2 | $120 |
| Ancora Heart, Inc. | 1 | $73 |
| Endotronix, Inc. | 1 | $58 |
| Getinge USA Sales, LLC | 1 | $18 |
| Sensible Medical Innovations Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$50,211
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$39,606
- HeartWare HVAD$35,511
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$9,075
- CardioMEMS HF System$7,070
- CLINICAL TRIAL PRODUCT$6,200
- FreeStyle Libre Pro$6,000
- remede System$5,751
- Impella$4,215
- HeartMate 3 Left Ventricular Dev$3,402
- TherOx DS2 Console$2,500
- Catheter$2,500
- Downstream Cartridge$2,500
- Arctic Front$1,398
- HeartMate II LVAS$1,375
- HeartMate Touch$702
- Product in Development$600
- OPTIMIZER$520
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$325
- GENERAL - THERAPIES$141
How this compares
$1,105,328 in reported general payments places this provider in the 90th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 14 | $315,008 |
| Tyvaso DpiTreprostinil | 12 | $290,742 |
| JardianceEmpagliflozin | 128 | $115,345 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 11 | $73,261 |
| EntrestoSacubitril/Valsartan | 53 | $60,037 |
| EliquisApixaban | 19 | $29,762 |
| FarxigaDapagliflozin Propanediol | 26 | $27,403 |
| Repatha SureclickEvolocumab | 13 | $8,146 |
| Icosapent Ethyl | 11 | $4,748 |
| Tacrolimus | 39 | $3,936 |
| Bumetanide | 70 | $3,724 |
| Warfarin Sodium | 70 | $2,366 |
| Dofetilide | 22 | $1,281 |
| Rosuvastatin Calcium | 38 | $1,199 |
| Bisoprolol Fumarate | 51 | $1,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $120 | $115,345128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in San Francisco
- Mandar ArasSan Francisco$1.2M
- Marc SimonSan Francisco$651K
- Teresa de MarcoSan Francisco$366K
- Ranjan RaySan Francisco$216K
- Shweta MotiwalaSan Francisco$127K
- Michael PhamSan Francisco$126K
- Michael MartynSan Francisco$93K
- Jared HerrSan Francisco$82K
- van SelbySan Francisco$40K
- Ronald WittelesStanford$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.